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Purpose: A pericentral pattern of hydroxychloroquine (HCQ) retinopathy recently has been recognized in the
United States in patients of Asian heritage. We report on an investigation of this pericentral retinopathy within a
Korean population.
Design: Retrospective, observational study.
Participants: Patients taking HCQ who were referred to ophthalmology for screening of HCQ retinopathy.
Methods: The medical records of patients were reviewed, including spectral domain optical coherence
tomography, fundus autoﬂuorescence, and visual ﬁelds.
Main Outcome Measures: Frequency of pericentral pattern of HCQ retinopathy and features of progression.
Results: Among 218 patients referred, 9 (4.1%) were diagnosed with toxicity. Of these, 8 had a predomi-
nantly pericentral pattern of retinal change, whereas only 1 had the classic parafoveal distribution of retinal
damage. Progression of retinopathy was documented in 3 patients followed more than 12 months while taking
HCQ. No progression was seen in 2 patients without retinal pigment epithelial (RPE) damage who were followed
for at least 12 months after discontinuation of HCQ.
Conclusions: We found that a pericentral pattern of HCQ retinopathy was predominant among Korean
patients, rather than the traditional (bull’s eye) parafoveal pattern of damage. Retinopathy progressed while on the
drug, but the progression stopped in patients with toxicity detected before RPE damage. These observations
suggest the need for new approaches when screening for HCQ toxicity in Asian
patients. Ophthalmology 2015;122:1252-1256 ª 2015 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Hydroxychloroquine (HCQ) is widely used for the treatment
of systemic lupus erythematosus, rheumatoid arthritis, and
other rheumatologic diseases. Previous studies suggested
that HCQ retinal toxicity was relatively rare1; however,
a recent report of patients who took HCQ for more
than 5 years reported an overall prevalence of 7.5%.2
Hydroxychloroquine retinal toxicity is generally
irreversible and may progress even after cessation of
drug.1,3 Thus, recognition of retinopathy at an early stage
is important.
Hydroxychloroquine toxicity traditionally has been
characterized as a parafoveal bull’s eye retinopathy, evident
in late stages as a ring of depigmentation about the fovea
and in earlier stages as a tight ring scotoma on 10-2 ﬁelds4,5
or parafoveal thinning of the outer nuclear layer with
breakup of the ellipsoid zone (EZ) and interdigitation zone
(IZ) lines on spectral domain optical coherence tomography
(SD OCT).6 However, a recent report based on a diverse
group of patients in the United States found that patients
of Asian heritage frequently developed retinopathy in a
more peripheral or “pericentral” pattern.7
This new ﬁnding has not been conﬁrmed in Asia. We
reviewed the records of patients who were referred to a
retina service in Seoul, Korea, for HCQ toxicity screening to
determine the distribution of retinopathy. We also report the1252  2015 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Incprogression of retinopathy while patients continued taking
HCQ and after stopping the medication.Methods
We reviewed the records of all patients who were referred for HCQ
screening to the department of ophthalmology at the Asan Medical
Center in Seoul Korea from 2011 to 2014. Data collected included
age, sex, medical diagnosis, weight, refractive status, daily dose,
duration of HCQ use, and cumulative dose of HCQ. The cumu-
lative dose data were collected through an automated pharmacy
system.
Detailed ophthalmic examination and ophthalmic ancillary tests
included 10-2 or 30-2 visual ﬁelds (VFs) (Humphrey perimeter;
Carl Zeiss Meditec Inc, Dublin, CA), SD OCT (Heidelberg Engi-
neering, Heidelberg, Germany), and fundus autoﬂuorescence
(FAF) (Heidelberg Engineering). The SD OCT studies were read
by 2 authors (D.H.L., Y.H.Y.), and a diagnosis of toxicity required
agreement on the presence of bilateral discrete macular zones of EZ
or IZ discontinuity. Patients were followed for a total of 6 to 30
months and for 2 to 18 months after retinopathy was diagnosed and
the drug was discontinued. Several patients were checked with
wide-angle FAF and swept-source optical coherence tomography
to evaluate retinal structural changes outside the arcade. This study
was approved by the Institutional Review Board and Ethics
Committee of Asan Medical Center..
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Table 1. Comparison between the Patients with Toxicity and Those Without
Patient Characteristics, No. (%) Retinal Toxicity No Retinal Toxicity P Value*
Female sex 9 (100.0) 182 (87.1) 0.61
Primary indication
Systemic lupus erythematosus 6 (66.7) 148 (70.8) 0.72
Rheumatoid arthritis 3 (33.3) 52 (24.9) 0.70
Other 0 9 (4.3) NA
Kidney diseasey 2 (22.2) 40 (19.1) 0.69
Liver disease 1 (11.1) 13 (6.2) 0.46
Patient Characteristics, Mean (SD)
Age (yrs) 54.1 (12.4) 46.2 (12.4) 0.06
HCQ daily dose (mg/kg) 4.2 (1.3) 3.8 (0.9) 0.17
Duration of HCQ use (mo) 115.8 (30.8) 99.8 (46.5) 0.31
HCQ cumulative dose (g) 991.9 (385.5) 729.8 (341.1) 0.03
Refractive error (D)z 0.19 (2.31) 1.51 (2.52) 0.14
D ¼ diopters; HCQ ¼ hydroxychloroquine; NA ¼ not available; SD ¼ standard deviation.
*Fisher exact test or Student t test.
yKidney disease deﬁned as a period of >3 months with glomerular ﬁltration rate <60 ml/min/1.73 m2.
zAverage spherical equivalent, excluding patients with prior cataract or refractive surgery.
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Of 218 patients reviewed, 9 (4.1%) showed discrete EZ-IZ loss on
SD OCT suggestive of HCQ toxicity. Although the mean age, daily
dose, duration of use, and cumulative dose were all greater in the
patients with toxicity compared with those without (Table 1), only
the difference in cumulative HCQ dose was statistically signiﬁcant
(P ¼ 0.03). Patients with toxicity were slightly less myopic on
average than those without.
Table 2 shows demographic and dose information for the
patients with toxicity. The patients with outer retinal changes
consistent with HCQ retinopathy were separated into those with
a pericentral or parafoveal pattern. Eight patients with outer
retinal loss more than 7 from the fovea were classiﬁed as
having pericentral retinopathy, whereas only 1 patient had outer
retinal changes in the classic bull’s eye pattern 2 to 6 from the
fovea. Figure 1 illustrates the ﬁndings of pericentral retinopathyTable 2. Demographic and Dose Inform
Case Identiﬁers Age (yrs) Sex Diagnosis Weight (kg)
Mean Refrac
Error (D
Pericentral Pattern
1 53 F SLE 47 0.69
2 38 F SLE 53 5.44
3* 34 F SLE 48 0.06
4y 66 F SLE 55 1.75
5 67 F RA 54 1.94
6 55 F SLE 64 0.75
7 67 F RA 50 1.25
8 60 F RA 55 1.38
Parafoveal Pattern
9 47 F SLE 56 NA
D ¼ diopters; F = female; HCQ ¼ hydroxychloroquine; NA ¼ not available;
*History of renal disease and liver disease.
yHistory of renal disease, LASIK, and intraocular lens surgery.(case 1), including 30-2 VFs. The pericentral pattern of toxicity
was visible only at the periphery of 10-2 VF tests. Most of the
patients tested with the 30-2 protocol showed some mid-
peripheral losses, particularly in more advanced cases.
Because the SD OCT ﬁndings were unexpected or sometimes
ambiguous at ﬁrst examination (given the traditional description of
parafoveal retinopathy), and the initial 10-2 ﬁelds were not revealing,
some patients were followed while remaining on HCQ until damage
was clearly evident on SD OCT. Figure 2 shows the progression of
pericentral FAF in case 1. A hyperﬂuorescent zone in the inferior
temporal area appeared 12 months after the initial study (10 years
of HCQ therapy), and this zone enlarged and became more intense
on repeat FAF 6 months later, at which time the patient
discontinued HCQ. A wide-ﬁeld FAF of this same patient 27
months after the initial study is shown in Figure 1.
Three of the patients were followed at least 12 months
(maximum 24 months) while still taking HCQ. Figures 3 and 4ation for the Patients with Toxicity
tive
)
HCQ Daily
Dose/Weight (mg/kg) HCQ Duration (mos)
HCQ Cumulative
Dose (g)
4.3 134 1342
7.5 96 1053
4.2 52 379
3.6 98 396
3.7 141 1115
4.7 111 1054
4.0 151 1099
3.6 120 949
3.6 139 1540
RA ¼ rheumatoid arthritis; SLE ¼ systemic lupus erythematosus.
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Figure 1. Case 1. Top: Horizontal spectral domain optical coherence to-
mography of the right eye, showing loss of the outer retina (ellipsoid zone
and interdigitation zone) in the temporal retina.Middle: Wide-ﬁeld fundus
autoﬂuorescence showing a broad area of hyperﬂuorescence in the infero-
temporal macula. Bottom: 30-2 visual ﬁeld (VF) with superonasal scotoma
corresponding to the retinal changes. A 10-2 VF test showed normal
results.
Ophthalmology Volume 122, Number 6, June 2015show the SD OCT pattern of retinal anatomic changes while on
HCQ in cases 2 and 3, respectively, illustrating the pericentral
origin of damage in these eyes. There was little outer retinal
damage at the ﬁrst screening visits, but upon repeat screening 1 to 2Figure 2. Case 1. Fundus autoﬂuorescence images showing progressive hyperﬂu
(HCQ), which was discontinued after the 18-month study (11 years of HCQ t
1254years later, there is marked loss of the EZ and IZ in areas more than
7 eccentric from the fovea. Centripetal movement of the degen-
eration from a more peripheral origin is seen clearly in the left eye
of case 2, which had some early thinning at baseline in the far
temporal periphery of the SD OCT ﬁeld.
Three patients with retinopathy were also followed for at least
12 months (maximum 18 months) after discontinuation of HCQ,
which allows comparison of the degree of progression on and off
the drug. Two patients, whose toxicity was detected before any
retinal pigment epithelial (RPE) damage on SD OCT, showed no
further loss of EZ or IZ structures after HCQ was stopped. Figure 4
shows the right eye SD OCT of case 3, with clear progression
while on the drug from 0 to 12 months (when the drug was
discontinued), but no progression from 12 to 30 months. An
additional patient with some RPE damage apparent on SD OCT
(but not on FAF or fundus examination) was followed for 18
months after discontinuing HCQ and showed mild narrowing of
the EZ. The patient with classic parafoveal retinopathy had
marked RPE loss and showed prominent foveal thinning and
progressive loss of EZ over 9 months of follow-up off HCQ.
Discussion
We found that a newly described pattern of pericentral HCQ
retinopathy among Asian patients in the United States7 was
more prevalent among Korean patients with toxicity, as
opposed to the classic “bull’s eye” parafoveal pattern.
This ﬁnding strengthens the suggestion that we may need
to modify screening recommendations for HCQ toxicity in
Asian patients.7
The American Academy of Ophthalmology has recom-
mended regular ophthalmic screening for patients on long-
term HCQ therapy.8 The 10-2 VF test has been
highlighted as a key test for detecting the early HCQ
toxicity because of its sensitivity in the central
macula.5,9,10 However, very early VF damage may be
confused with nonpathologic variations, and some patients
do not perform ﬁelds reliably. Thus, the American Academy
of Ophthalmology guideline emphasized the importance of
adding objective testing such as SD OCT and multifocal
electroretinography where available. The use of multifocal
electroretinography for screening has been hampered by its
limited availability and variable interpretation, and so the
simultaneous use of VF and SD OCT tests is typicallyorescence in the inferotemporal macula while taking hydroxychloroquine
herapy).
Figure 3. Case 2. Horizontal spectral domain optical coherence tomography images showing progressive centripetal loss of the outer nuclear layer (white
arrows) over 24 months while taking hydroxychloroquine (8 years of therapy). The initial temporal change in the left eye (grey arrow) was not recognized as
toxicity. OD ¼ right eye; OS ¼ left eye.
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objective tests to detect and conﬁrm HCQ toxicity.4,8
Prior reports have shown a characteristic parafoveal loss
of the photoreceptor EZ-IZ junction on SD OCT in HCQ
retinal toxicity6,11 and have emphasized the necessity of
recognizing early thinning on OCT that is typically just 2 to
6 off the center.4 However, most of the patients in the
current study presented with outer retinal changes so far
from the fovea that they might not have been detected
with central VF testing or SD OCT scanning protocols
that did not go beyond 10 of the macula. The majority ofFigure 4. Case 3. Horizontal spectral-domain optical coherence tomog-
raphy images from the right eye showing different degrees of progression on
and off hydroxychloroquine (HCQ) in a patient with renal disease. The
baseline examination (top) was performed after 3 years of HCQ therapy
and showed no outer retinal damage. A loss of outer retinal structures
temporally was seen 12 months later (middle, white arrow) was visible, and
HCQ was discontinued. There was no evidence of further progression
(bottom, white arrow) over the next 18 months off the drug.our patients had EZ-IZ loss in perifoveal and even mid-
peripheral areas that sometimes resembled the optical
coherence tomography ﬁndings of patients with pericentral
retinitis pigmentosa. Only 1 patient showed the classic
bull’s eye parafoveal damage.
Because this peripheral pattern was not an expected
presentation of HCQ retinopathy, a number of patients were
followed until the cause of damage became clear. Continued
use of HCQ (for at least 1 year) showed a steady centripetal
progression of EZ-IZ disruption and FAF hyper-
ﬂuorescence. There was also further loss of the EZ after
stopping the drug in eyes with RPE involvement. In
contrast, patients who discontinued HCQ therapy at an
earlier stage of retinopathy (no RPE damage) did not show
signiﬁcant progression. This is an important observation
because it demonstrates the speed with which retinopathy
damage can occur while taking HCQ and the importance of
detecting damage before progression into the fovea. Our
series is too small for ﬁrm conclusions, but these observa-
tions are consistent with prior reports that there is little or no
progression of EZ-IZ loss in patients with parafoveal reti-
nopathy before RPE disruption.12
Hydroxychloroquine binds to melanin in the RPE and
causes lipid complex accumulation, enzyme inhibition, free
radical generation, and ion disturbances in the retina.13e19
However, the pathophysiology of the retinal toxicity and its
central distribution are not clearly understood, nor is there an
obvious explanation for the disparity in the retinal location
between white and Asian patients. An increased risk in pa-
tients with more retinal pigment seems unlikely because black
patients do not seempredisposed to the peripheral pattern,7 nor
is myopia likely because the average refractive error was low
among the patients with toxicity (and a review of the data from
an American study7 showed no correlation with refractive
status). Unusual dosing is not a factor because only 1 patient
with retinopathy had received excessive daily dosage
relative to a recent report that suggested lower risk at
<5 mg/kg.2 One study has suggested that aberrations in the
ABCA4 gene may predispose to HCQ toxicity,20 although
this has not been corroborated. Patients in that study would
have been mostly of European ancestry, and perhaps future
genetic studies will help to clarify the impact of racial
differences on patterns of toxicity.1255
Ophthalmology Volume 122, Number 6, June 2015In conclusion, the pattern of early HCQ toxicity differs
between Korean patients and patients of European descent.
Most Korean patients show pericentral rather than parafoveal
photoreceptor damage, and the toxicity progresses in a cen-
tripetal fashion toward the fovea while on the drug. However,
in both groups, progression appears to stop if the medication
is discontinued at an early stage of retinopathy. On the basis
of these observations, we propose that screening protocols for
detecting HCQ toxicity in Korean and other Asian patients
include wide-ﬁeld examinations, such as 24-2 or 30-2 VF
protocols, wide-ﬁeld FAF, or SDOCTwith at least 30 scans.
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